Literature DB >> 8195878

Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease.

A M Catafau1, E Parellada, F J Lomeña, M Bernardo, J Pavía, D Ros, J Setoain, E Gonzalez-Monclús.   

Abstract

UNLABELLED: This study assesses prefrontal and temporal regional cerebral blood flow (rCBF) changes in young, neuroleptic-naive schizophrenic patients with acute disease.
METHODS: A selected population of 10 young, never-treated schizophrenic women with acute disease was studied by two hexamethylpropyleneamine oxime (HMPAO) brain SPECT sessions, performed 48 hr apart, both at rest and during a prefrontal activation task using the Wisconsin Card Sort Test (WCST). All patients met Diagnostic and Statistical Manual of Mental Disorders, 3rd edition-revised criteria for schizophrenia or schizophreniform disorder, were neuroleptic-naive and had acute symptoms.
RESULTS: Under resting conditions, the schizophrenic group had significantly higher rCBF in the prefrontal regions, mainly in the left side and including the anterior cingulate, than did the controls. In addition, schizophrenic patients showed significant interhemispheric differences in prefrontal and posterior temporal index values at rest (left hyperfrontality and left hypotemporality). During WCST activation, the control group showed significant increases in prefrontal blood flow, whereas the schizophrenic group did not.
CONCLUSION: These results support a physiologic dysfunction of the prefrontal cortex in schizophrenia that is present at the onset of the illness prior to neuroleptic treatment. Furthermore, both left hyperfrontality and left hypotemporality may indicate a brain lateralization defect in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195878

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  34 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  Spontaneous brain activity observed with functional magnetic resonance imaging as a potential biomarker in neuropsychiatric disorders.

Authors:  Yuan Zhou; Kun Wang; Yong Liu; Ming Song; Sonya W Song; Tianzi Jiang
Journal:  Cogn Neurodyn       Date:  2010-08-03       Impact factor: 5.082

Review 3.  Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism.

Authors:  J D Ragland; J Yoon; M J Minzenberg; C S Carter
Journal:  Int Rev Psychiatry       Date:  2007-08

4.  Comparison of Classical and Clozapine Treatment on Schizophrenia Using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT Imaging.

Authors:  Mohammad Sharafi
Journal:  Int J Med Sci       Date:  2005-05-10       Impact factor: 3.738

Review 5.  On the measurement of the effects of alcohol and illicit substances on inhibition of return.

Authors:  Janine V Olthuis; Raymond M Klein
Journal:  Psychopharmacology (Berl)       Date:  2012-05-09       Impact factor: 4.530

6.  Regional cerebral blood flow pattern in normal young and aged volunteers: a 99mTc-HMPAO SPET study.

Authors:  A M Catafau; F J Lomeña; J Pavia; E Parellada; M Bernardo; J Setoain; E Tolosa
Journal:  Eur J Nucl Med       Date:  1996-10

7.  Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study.

Authors:  M Soyka; W Koch; H J Möller; T Rüther; K Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04-18       Impact factor: 5.270

8.  Cortical blood flow during rest and Wisconsin Card Sorting Test performance in schizophrenia.

Authors:  Felipe Ortuño; Miguel Moreno-Iñiguez; Manuel Millán; César A Soutullo; Raphael M Bonelli
Journal:  Wien Med Wochenschr       Date:  2006-04

Review 9.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 10.  Executive function, neural circuitry, and genetic mechanisms in schizophrenia.

Authors:  Daniel Paul Eisenberg; Karen Faith Berman
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.